Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy

Development and evaluation of an improved quantitative90Y bremsstrahlung SPECT method

(2012) Xing Rong et al.   MEDICAL PHYSICS

Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan or 131I-Tositumomab

(2010) S. Baechler et al.   JOURNAL OF NUCLEAR MEDICINE

90Y Bremsstrahlung Imaging for Absorbed-Dose Assessment in High-Dose Radioimmunotherapy

(2010) D. Minarik et al.   JOURNAL OF NUCLEAR MEDICINE

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

(2009) Dik J Kwekkeboom et al.   ENDOCRINE-RELATED CANCER

A novel view on dosimetry-related radionuclide therapy: Presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinoma

(2009) Alexander R. Stahl et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

(2009) Flavio Forrer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

124I PET-Based 3D-RD Dosimetry for a Pediatric Thyroid Cancer Patient: Real-Time Treatment Planning and Methodologic Comparison

(2009) R. F. Hobbs et al.   JOURNAL OF NUCLEAR MEDICINE

Calculation of the biological effective dose for piecewise defined dose-rate fits

(2009) Robert F. Hobbs et al.   MEDICAL PHYSICS

Peptide-receptor radionuclide therapy for endocrine tumors

(2009) Martijn van Essen et al.   Nature Reviews Endocrinology

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide

(2009) Raffaella Barone et al.   NUCLEAR MEDICINE COMMUNICATIONS

Estimates of Radiation-Absorbed Dose to Kidneys in Patients Treated with 90Y-Ibritumomab Tiuxetan

(2008) Sébastien Baechler et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

(2008) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response--Implications for Radionuclide Therapy

(2008) B. W. Wessels et al.   JOURNAL OF NUCLEAR MEDICINE

Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry

(2008) Sébastien Baechler et al.   MEDICAL PHYSICS